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Background: While previous research has provided evidence of the diagnostic accuracy of the GeneXpert MTB/
RIF (GeneXpert), further information is needed about implementation in the real-world. This study evaluated
the impact of the introduction of GeneXpert testing in a tertiary medical center according to the testing algo-
rithm proposed by the National TB Control Program (NTP) guidelines.
Methods: All adult medical inpatient persons with presumptive TB admitted between November 2013 and
March 2014 were eligible for GeneXpert sputum testing and followed to TB treatment initiation status.
Results: We identified 932 persons with presumptive TB, of which 307 (32.9%) were GeneXpert tested. Those
tested had an average age of 40 years, 49.2% (151) were male, 34.5% (106) were HIV positive, and 84.1%
(249) presented with a cough. Of those GeneXpert tested, 28/307 (9.1%) tested positive, a 55.5% increase in
detection compared to smear microscopy. However, the majority (44/72, 61%) of TB diagnoses were made by
other modalities and not confirmed microbiologically. Of the 58 patients recommended to start treatment
and discharged from the hospital, only 23 (40%) were documented to have started treatment at regional
directly observed treatment, short course (DOTS) centers.
Conclusions: GeneXpert contributed minimally to overall TB diagnosis and the cascade of care due to imple-
mentation challenges of sputum collection, empiric treatment, and weak linkage to care between inpatient
and outpatient settings.
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Introduction
TB is a leading cause of mortality among HIV co-infected indivi-
duals, with a disproportionate burden in Sub-Saharan Africa.1
Improving TB diagnostics is one strategy to reduce TB morbidity
and mortality.1 The conventional procedure for TB diagnosis is AFB
smear microscopy, which is a low-cost test with a high specificity
(90%).2,3 However, it is only able to identify 20–60% of incident TB
cases, with decreased detection abilities among HIV infected indi-
viduals.2–4 The GeneXpert MTB/RIF (GeneXpert) is a molecular diag-
nostic tool that has a rapid sample processing turnaround time
(less than 2 hours), high sensitivity (89%) and specificity (99%),
and the ability to detect rifampicin drug resistance.4,5 GeneXpert
increases TB case detection by 23% compared to AFB smear.5
While previous research has provided strong evidence of the
diagnostic accuracy of the GeneXpert,4 further information is
needed about real-world implementation in resource challenged
settings. GeneXpert implementation poses challenges related to
both infrastructure requirements for testing6–8 as well as
healthcare delivery related factors9,10 suggesting that expected
gains in treatment outcomes may be difficult to achieve. In
clinics in South Africa, while more TB cases were confirmed,
overall mortality and TB treatment initiation rates did not
change after implementation of GeneXpert.11
In concordance with the WHO recommendation, Malawi has
also adopted GeneXpert testing into national health policy.4,7,12
The Malawi National TB Control Program (NTP) has endorsed
screening hospitalized persons with presumptive TB with
GeneXpert.12 In this setting, the dual burden of HIV and TB,
representing 38%13 and 16%14 of admission diagnoses, empha-
sizes the potential importance of the assay in this population.
© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.
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This study evaluated the impact of the introduction of
GeneXpert testing in a tertiary medical center according to the
testing algorithm proposed by the NTP guidelines.12 In addition,
we evaluated the cascade of care for TB, from screening to
detection to treatment status.
Materials and methods
Study setting and population
Kamuzu Central Hospital (KCH) is a 1000 bed tertiary referral
facility in Lilongwe, Malawi with approximately 5000 admissions
to the adult medical wards per year.14 All patients admitted to
the medical wards and >14 years of age, from November 2013
through March 2014, were eligible. The NTP protocol recom-
mends GeneXpert testing for all patients that present with
‘danger signs’ and have TB-related symptoms.12 ‘Danger signs’
were defined as ‘respiratory rate >30 per min, temperature
>39oC, heart rate >120 beats per minute, patient confused or
agitated, respiratory distress, systolic blood pressure <90
mmHg or inability to walk unassisted.’12 Patients self-reporting
with recent fever, cough, night sweats or weight loss for any
period of time should be suspected of and tested for TB.12
Study design
We conducted a prospective study of all KCH adult inpatients to
assess the impact of GeneXpert detection of TB cases in the
wards and initiation of TB treatment.
Screening and testing procedures
Routine HIV testing was conducted in the wards by trained HIV
testing (HTC) counselors. The counselors systematically screened
and offered testing to all patients admitted to the wards.
Patients with an unknown HIV status or a negative HIV test
(>3 months ago) were offered opt-out HTC by the counselor
(serial testing with HIV 1/2 and Unigold HIV 1/2).15 The results
of the test were then recorded in the patient’s file.
Before implementation of the new guidelines, TB testing was
initiated by the medical provider and sputum samples were
tested using AFB smear at the KCH lab. Provider-initiated diag-
nostic methods such as chest x-ray, ultrasound, or fine needle
aspiration were also utilized to aid in TB diagnosis. TB diagnosis
and management was followed according to standard hospital
protocol.
Kamuzu Central Hospital and the Malawi National TB
Control Program protocols
During implementation, we conducted TB screening and applied
the NTP GeneXpert testing protocol.12 All patients triaged from
the short stay, or acute care, and subsequently admitted as an
inpatient were presumed to meet the criteria for ‘danger signs’
based on hospital threshold for admission. A clinical officer, an
existing Ministry of Health staff, was trained as the ‘TB screening
champion.’ The clinical officer identified all admissions within
the past 24 hours (recorded in the ward nurse’s admission logs)
and screened for all patients with TB symptomology. These
admitted patients that initially presented with ‘danger signs’
and had relevant symptomology were defined as ‘persons with
presumptive TB’. Patients were asked to produce one sputum
sample into a labeled container. Samples were collected by the
clinical officer or placed in a designated collection location in
the wards by the patient’s guardian, if the patient could not
expectorate immediately. No sputum induction process was
available as per standard hospital protocol.16 Clinic aides trans-
ported samples from the wards to the lab facility and testing at
the lab facility took place Monday through Friday, 08:00 to
17:00 h. Results were communicated with the patient’s medical
care team as soon as they were available, between 08:00 and
17:00 h during weekdays.
In concordance with Malawi guidelines for GeneXpert, one
sputum specimen per patient was obtained with coaching from
the clinical officer.12,16 The sample was processed adhering to
the standardized protocol and quality control procedures of the
UNC Project laboratory. GeneXpert testing was performed on the
sputum sample according to the manufacturer’s operation
instructions. Additionally, fluorescence microscopy was used to
examine smears for AFB. Smear positive results were determined
by reporting Mycobacterium tuberculosis density, defined as
scanty, 1+, 2+, or 3+. All test results were interpreted by trained
laboratory personnel who were not blinded to the GeneXpert test
result. The time of sample collection in the wards, receipt of sam-
ple at the lab, and processing of results was recorded.
Data collection
A survey tool was used to collect demographic characteristics,
address, patient ID number, symptoms and date of admission.
The patient’s phone contact information was recorded, in the
event that test results were not available until after their dis-
charge. HIV status was obtained from patient medical files, as
HIV status was noted on medical charts by the HTC counselors.
Review of patient files was performed weekly to abstract hospi-
talization outcome (death, discharge, abscond or transfer), date
of outcome, and results of additional diagnostics (chest x-ray,
ultrasound or fine needle aspiration). Any missing information of
clinical characteristics was also extracted from the patient med-
ical files.
Date of TB diagnosis was gathered from the patient medical
files as treatment is not initiated on the wards. When the diag-
nosis of TB is confirmed, patients are transferred for inpatient
hospitalization or discharged to receive outpatient therapy at
the local directly observed treatment, short course (DOTS) center.
All inpatient and outpatient TB patients register at one of the
regional DOTS centers in order to receive therapy.
Patients were traced to a DOTS center in the Lilongwe
District, where they were most likely to receive care based on
their address. TB officers at each of the 15 sites were sent a list
of patients who were diagnosed with TB at KCH. The officers
then cross-referenced the patient information provided
(patient’s name, age and address) to the listings in the registry
to determine if the patient had initiated treatment. The TB offi-
cers scanned the chronologically organized registries matching
patients based on their date of discharge from KCH up to one
month post-discharge. The Central District TB Officer of Bwaila
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District Hospital in Lilongwe, Malawi also conducted random site
visits to check on the accuracy of the matching.
Statistical analysis
The primary outcome measures were the number of persons
with presumptive TB tested, GeneXpert-positive patients and
number recommended to start TB treatment. We used frequency
and percentages to describe patient characteristics. Categorical
variables were compared using Pearson’s χ2 test. The change in
TB case detection during GeneXpert implementation phase was
calculated by comparing the proportion of GeneXpert-positives to
the proportion of smear positives, stratified by HIV status.
Programmatic factors were assessed by the length of time
between date of admission, date of sample collection and date
of result availability. Lastly, the proportion of patients registered
for TB therapy at the Central district DOTS facilities was compared
to all recommended to start TB treatment at KCH to measure
linkage to care. All data was entered into an Access database
(Microsoft Corp., Redmond,WA, USA) and analyzed using STATA 13
(StataCorp LP, College Station, TX, USA).
Ethics
No consent process was necessary as TB testing is part of
standard of care. Ethics approval was obtained from the Malawi
National Health Science Research Committee and the University
of North Carolina Medical School institutional review board.
Results
Characteristics
During the 4 month study period, 1936 patients were admitted
to the medical wards, and 932 (48.1%) were identified as per-
sons with presumptive TB (Figure 1); 51.8% (483) of persons
with presumptive TB were under 30 years of age with a male to
female ratio of 1.2:1. The most common symptoms were cough
(454, 48.7%) and fever (604, 64.8%). Among persons with pre-
sumptive TB, 288 (30.4%) were HIV reactive, 236 (25.3%) were
HIV nonreactive, and 408 (43.8%) were of unknown status.
Implementation assessment
Of the 932 persons with presumptive TB, 307 (32.9%) were
GeneXpert tested. In general, the gender distribution and HIV
status among the persons with presumptive TB who were
GeneXpert tested versus not tested were similar (Table 1). The
primary reason persons with presumptive TB were not tested
was failure to produce sputum (351, 37.7%) and notably, this
group had a decreased frequency of cough as a primary symp-
tom compared to those tested (33.9% vs 84.1%, p<0.0001).
The median length of time from admission to the wards to
sample collection was 1 day (IQR 0–3) (Table 2). The median
time from admission to GeneXpert result was 3 days (IQR 2–5).
Lastly, the median time between hospital admission to recom-
mendation to start TB treatment, based on a GeneXpert positive
result, was 6 days (IQR 4–8).
GeneXpert tested
Among the 307 inpatients tested, 28 (9.1%) were GeneXpert posi-
tive (Table 3). No rifampicin resistance mutations were detected.
The GeneXpert detected an additional 10 TB cases or increased
TB detection by approximately 55.5%, compared to AFB smear.
All AFB smear positives were also GeneXpert positive. Of the
11 GeneXpert positive-HIV positive patients, only six (54.5%)
were detected by AFB smear. Demographics, symptoms and HIV
status were similar according to GeneXpert status (Table 1)
TB treatment
Out of 932 suspects, a total of 72 (7.7%) were recommended to
start TB treatment. Of these, 28 (39%) were diagnosed with TB
based on a positive GeneXpert results. Forty-four (61%) TB diag-
nosis were based on other modalities or clinical suspicion, of
which 22 (31%) of patients were diagnosed on clinical suspicion
and 22 (31%) were diagnosed with TB on evidence of radio-
logical/histological evidence. All patients with a positive
GeneXpert were started on TB therapy regardless of clinical,
histological or radiological findings.
A total of 17 patients were GeneXpert-negative and recom-
mended to start TB treatment. Twelve (71%) had radiographic
evidence of TB (11 chest x-ray suggestion of TB, one abdominal
ultrasound suggestion of TB). A majority of these GeneXpert-
negative TB patients presented with cough (17, 100%) and were
HIV positive (11, 65%).
A total of 27 patients were not GeneXpert tested and recom-
mended to started TB treatment. 10/27(37%) had radiographic
or histologic suggestion of TB. The remainder, 17 patients, were
diagnosed based on clinical suspicion.
Of all patients recommended to initiate TB treatment, 14
(19%) died during the hospitalization. Of the 58 patients recom-
mended to start treatment and discharged from the hospital,
only 23 (40%) were documented to have initiated treatment at
TB registration facilities in the Lilongwe district within 1 month
of discharge from KCH.
Total number of admissions
1936
Total number of persons with presumptive TB
932 (48.1%)
GeneXpert + AFB smear
307 (32.9%)
Not TB suspect: 1004 (51.9%)
*Died: 149
*On TB treatment: 44 
1.Discharged/not found: 195
2.Too sick: 6
3.Unable to produce sputum: 351
4.Reason not documented: 73
Figure 1. Flowchart of study participants. All inpatients admitted to the
general male and female medical wards were screened for TB symp-
toms. They were defined as persons with presumptive TB if they met the
criteria for danger signs and TB symptomology as described by the
Malawi National TB Control Program (NTP) Manual.
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Table 1. Demographic and clinical characteristics of all persons with presumptive TB (n=932)
Characteristics Persons with presumptive TB
Not GeneXpert tested
(n=625)
GeneXpert tested
(n=307)
GeneXpert positive
(n=28)
GeneXpert negative
(n=279)
Frequency (%)
Gender
Male 363 (58.1%) 151 (49.2%) 13 (46.4%) 138 (49.5%)
Female 262 (41.9%) 156 (50.8%) 15 (53.6%) 141 (50.5%)
Agea
14–20 241 (44.1%) 19 (6.2%) 1 (3.6%) 18 (6.5%)
21–30 136 (24.9%) 87 (28.3%) 12 (42.9%) 75 (26.9%)
31–40 62 (11.4%) 84 (27.4%) 11 (39.3%) 73 (26.2%)
41–50 42 (7.7%) 47 (15.3%) 1 (3.6%) 46 (16.5%)
>50 65 (11.9%) 70 (22.8%) 3 (10.7%) 67 (24.0%)
Clinical featuresb
Cough 205 (33.9%) 249 (84.1%) 23 (85.2%) 226 (84.0%)
Fever 482 (79.8%) 122 (41.2%) 9 (33.3%) 113 (42.0%)
Night sweats 79 (12.6%) 47 (15.9%) 7 (25.9%) 40 (14.9%)
Weight loss 115 (19.1%) 50 (16.9%) 7 (25.9%) 43 (16.0%)
Hemoptysis 14 (2.3%) 14 (4.7%) 1 (3.7%) 13 (4.8%)
Shortness of breath 99 (16.4%) 37 (12.5%) 3 (11.1%) 34 (12.6%)
HIV status
Positive 182 (29.1%) 106 (34.5%) 11 (39.3%) 95 (34.1%)
Negative 171 (27.4%) 65 (21.2%) 1 (3.6%) 64 (22.9%)
Unknown 272 (43.5%) 136 (44.3%) 16 (57.1%) 120 (43.0%)
Outcomec
Discharged 413 (81.5%) 213 (90.3%) 13 (92.9%) 200 (90.1%)
Death 83 (16.4%) 23 (9.8%) 1 (7.1%) 22 (9.9%)
Absconded 4 (0.8%) NA NA NA
Transferred 7 (1.4%) NA NA NA
Patients could have more than one clinical feature, so percentages of patients with each feature does not add to 100%.
a 79 missing age values for persons with presumptive TB not tested.
b 21 missing clinical features values among persons with presumptive TB-not tested; 118 missing outcomes values for persons with presumptive
TB-not tested.
c 11 missing clinical features values among persons with presumptive TB tested, 71 missing outcomes values among persons with presumptive
TB tested.
d 1 missing clinical features value among GeneXpert positives, 14 missing outcome values among GeneXpert positives.
e 10 missing clinical features values among GeneXpert negatives, 57 missing outcome values among GeneXpert negatives.
NA: not available.
Table 2. Turnaround time of the GeneXpert MTB/RIF and TB diagnosis in routine inpatient care at Kamuzu Central Hospital (KCH)
Time intervals Median time, days IQR 25–75
n=307
Date of admission to sample collection 1 0–3
Date of admission to GeneXpert result (from lab) 3 2–5
Date of admission to diagnosis of TB at KCH (GeneXpert positive) 6 4–8
K. S. Chawla et al.
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Discussion
Our study evaluated the impact of GeneXpert roll-out on TB
diagnosis and treatment among inpatients in a resource chal-
lenged health care facility in Sub-Saharan Africa. The overall
contribution of GeneXpert testing was small due to initiation of
empiric therapy based on clinical symptoms and other diagnos-
tics. Furthermore, there was low diagnostic impact due to oper-
ational challenges, such as difficulty with sputum sampling and
slow turnaround time in a high volume setting. We also noted
gaps in the continuum of care after discharge from the hospital.
These findings suggest that implementation of the GeneXpert
may not provide substantial change in patient outcomes in real
world settings unless additional barriers are addressed.
Empiric treatment
In our study, TB case detection increased only modestly among
persons with presumptive TB after the implementation of
GeneXpert. Despite GeneXpert implementation, initiation of TB
treatment was disproportionately based on empiric treatment
(61%), a process of diagnosing TB based on clinical suspicion
and radiological findings and without bacteriological confirm-
ation.17 Our findings are similar to other studies in South Africa
and Uganda that also reported this paradoxical phenomenon of
high utilization of empiric treatment in the GeneXpert era.16,18,19
Notably, even in settings with extensive diagnostics, TB can be
missed. Autopsy studies in both the pre and post ART eras have
demonstrated high rates of undiagnosed TB infection.20,21
Physicians working in such environments may start patients on
empiric therapy based on factors such as failure of antibiotic
treatment, clinical danger signs, low healthcare access environ-
ment, delay in GeneXpert results, positive results using other
radiologic modalities, or high patient mortality rate.22–24 Overall,
these findings suggest that empiric TB therapy is prevalent
although the impact on patient outcomes is currently the sub-
ject of clinical trials.
Gaps in diagnosis
Among persons with presumptive TB started on empiric TB
treatment, a large proportion of patients were GeneXpert-
negative or sputum scarce. Multiple previous studies have also
documented this phenomenon.25 In high HIV-TB burden envir-
onments, empiric treatment is often used to offset the diagnos-
tic limitations and provide, possibly, same day treatment to
decompensating patients.21–25 The few studies presenting diag-
nostic information on GeneXpert negative individuals suggest
that smear microscopy and chest x-ray have limited utility in
detecting culture positive, Xpert negative, extrapulmonary or
disseminated TB.6,11 For sputum scarce patients, rapid diagnos-
tics using other samples such as urine (urine LAM or urine
GeneXpert) or blood may prove more feasible for testing.
Overall, further guidelines are needed to address these gaps in
diagnosis for GeneXpert negative and sputum scarce patients.25
Mortality
We observed high in-hospital mortality rates among TB cases.
First, our observed rate was congruent with TB mortality rates in
other high-HIV prevalence settings (18–27%).17,26,27 GeneXpert
testing is expected to affect a decrease in mortality, presumably
due to earlier diagnosis, thus earlier treatment. However, in hos-
pital settings, TB disease may be sufficiently advanced that
adverse outcomes are difficult to modify. Factors such as delay
to presentation28 or atypical presentation29 may contribute to
severe hospital presentations. The high in-hospital mortality rate
confirms the need intensified case finding with GeneXpert fur-
ther upstream, at the patient’s first encounter with the health-
care system, in contrast to our referral medical facility.17
Multiple healthcare environment factors and patient character-
istics are important to consider and target in order to reduce
mortality among patients with TB.
Programmatic challenges
The 6 day turnaround time from admission to GeneXpert result,
performed in a controlled research lab, was reduced compared
to the 8 days for AFB smear results as reported in 2005.30
Programmatic challenges were similar to previous reports,
including delays with updated patient logs, sample submission,
lab forms, transport of samples, result-to-clinical decision, and
result-to-patient linkage.31–33 This shows that hospital related
work flow factors need to be improved simultaneously in order
to gain full benefit of rapid diagnosis, particularly if sample vol-
ume is high. Task shifting TB screening to HTC counselors could
Table 3. Comparison of GeneXpert MTB/ RIF vs AFB smear results, stratified by HIV status (n=307)
HIV positive n=106 (%) HIV negative n=65 (%) Unknown n=136 (%)
GeneXpert MTB/ RIF
Positive 11 (10.3) 1 (1.5) 16 (11.8)
Negative 95 (89.7) 64 (98.5) 120 (88.2)
AFB Smeara
Positive 6 (5.6) 1 (1.5) 11 (8.0)
Negative 100 (94.4) 64 (98.5) 125 (92.0)
aEach patient had a GeneXpert MTB/RIF and AFB smear test on a sputum sample, so two observations per patient.
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leverage existing infrastructure and staff capacity to manage
increased TB suspect workload.33–35 Other hospital related fac-
tors that could be targeted for improvement include communi-
cation between clinical staff and patients, documentation,
coordination of care, and patient flow and tracking.19,30,31
Linkage to care
While GeneXpert diagnosis did contribute to increased TB case
detection, only 40% (23/58) were documented to have initiated
treatment by registering at a TB registration center. This may be
an underestimate as patients may have registered at a Central
Region facility or inconsistency in matching names between
registries. However, this finding is consistent with previous find-
ings of loss to care in the TB care cascade.36 Significant barriers
to care include transportation costs, stigma and increased bur-
den due to concomitant TB therapy and ART.37–39 We suggest
that TB control strategies should integrate strategies to elimin-
ate gaps in the spectrum of care.
Our study is reflective of the programmatic challenges with
implementation of an intervention in a routine hospital care set-
ting and assessment of linkage to care, which presents some
limitations. Approximately 20% of patient files were missing,
leading to incomplete information regarding hospital outcomes.
However, all patient files of those who had died were retained
by the hospital ward clerks, such that we had 100% mortality
ascertainment. Lastly, verification bias was present as not all
persons with presumptive TB were GeneXpert tested and no
confirmatory testing with culture was conducted. Likewise, spu-
tum induction and collection of >1 sputum sample may
increase diagnostic yield. However, this aligned with the NTP
guidelines, which do not include culture for initial diagnosis, and
impact evaluation directly relevant to our setting.
Conclusions
Our pragmatic study of the implementation of the GeneXpert
revealed only modest improvements in confirmed TB diagnosis
and was limited by challenges in the implementation of the NTP
algorithm. The current GeneXpert testing guidelines do not
address the existing gaps in TB diagnosis, which are bridged by
empiric-based TB diagnosis. Although our sample size was
small, the blunted impact of the GeneXpert on diagnosis and ini-
tiation of TB treatment further emphasizes the need to identify
alternative screening strategies to maximize utility and cost
effectiveness of GeneXpert test.
Further investigation in the inpatient setting is needed to
understand the accuracy of empirical TB treatment.
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